By Naomi Pearce
FCA Confirms Commonwealth may Claim Relief Under “Usual Undertakings as to Damages”
The much anticipated Court of Appeal decision in Commonwealth of Australia v Sanofi ¹ was handed down on Monday. The decision is a win for the Commonwealth, and for generic/biosimilar companies in Australia, and (if upheld in any appeal) will result in Sponsors adopting a more circumspect approach to seeking interlocutory injunctions for patent infringement in Australia.
Except where a generic/biosimilar applicant has “cleared the way” (cleared any patent impediments to launch through the Courts in Australia) or all relevant patents have expired, interlocutory injunctions are routinely sought by the Sponsor, and are routinely granted.
In order to get an interlocutory injunction in Australia, the applicant (here the Sponsor) will generally be required to provide an undertaking as to damages. In the “usual undertaking as to damages”, the Sponsor undertakes to submit to orders the Court deems fit to compensate any person adversely affected by the interlocutory order in the event that it is ultimately overturned.
Until now, the risk of the Commonwealth seeking compensation for losses resulting from a prolonged PBS price premium (whilst the generic/biosimilar medicine is kept off the market because of the injunction) has been theoretical. Now it is very real.
The decision has confirmed that the Commonwealth may seek relief under the “usual undertaking as to damages”. After a detailed analysis of the certification requirements and related remedies of the Therapeutic Goods Act², the Court of Appeal confirmed that those provisions do not limit the ability of the Commonwealth to claim under the usual undertaking.
The impact of this decision is significant, if upheld in any appeal to the High Court. Leaving aside any compensation payable to the generic/biosimilar company for delayed market entry, the amount claimed against Sanofi by the Commonwealth is $54.8M for the foregone/delayed 12.5% PBS price reduction.
The pendulum may have started to swing back toward a moderate position regarding interlocutory relief in Australia. Product sponsors will have good reason to pause before seeking interlocutory relief on vulnerable patents in Australia; generic/biosimilar manufacturers may be afforded greater opportunities to launch “at risk”, without interlocutory prohibitions; and the Commonwealth (and the public) will be compensated for delays to competition due to interlocutory injunctions which are ultimately overturned.
Please click here to view the decision.
¹  FCAFC 172
² Chapter 3, Part 3-2, Division 2 of the Therapeutic Goods Act 1989